ZLDPY (Zealand Pharma AS) E10: $0.06 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZLDPY Zealand Pharma AS ZLDPY
42 GF Score
Price $9.31
GF Value $393.56
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Zealand Pharma AS E10?

Zealand Pharma AS ZLDPY 42 E10 is $0.06 as of Jun. 2026. GuruFocus rates ZLDPY with a GF Score™ of 42/100 and a GF Value™ of $393.56 (Possible Value Trap). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Zealand Pharma AS's adjusted earnings per share data for the three months ended in Jun. 2026 was $1.705. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.06 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average E10 Growth Rate was 30.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Zealand Pharma AS was 30.30% per year. The lowest was -43.60% per year. And the median was -24.65% per year.

As of today (2026-08-16), Zealand Pharma AS's current stock price is $9.31. Zealand Pharma AS's E10 for the quarter that ended in Jun. 2026 was $0.06. Zealand Pharma AS's Shiller PE Ratio of today is 155.17.

During the past 13 years, the highest Shiller PE Ratio of Zealand Pharma AS was 167.17. The lowest was 142.42. And the median was 152.53.


Zealand Pharma AS  (OTCPK:ZLDPY) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Zealand Pharma AS's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=9.31/0.06
=155.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Zealand Pharma AS was 167.17. The lowest was 142.42. And the median was 152.53.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Zealand Pharma AS E10 Related Terms


Zealand Pharma AS E10 Historical Data

* Premium members only.

The historical data trend for Zealand Pharma AS's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS E10 Chart

Zealand Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.13

Zealand Pharma AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.06 -0.13 -0.14 0.06

ZLDPY vs VRTX, REGN, RVMD: E10 Comparison

For the Biotechnology subindustry, Zealand Pharma AS's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma AS Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Shiller PE Ratio falls into.


ZLDPY
42GF Score
Zealand Pharma AS ZLDPY
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zealand Pharma AS E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zealand Pharma AS's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.705/122.9700*122.9700
=1.705

Current CPI (Jun. 2026) = 122.9700.

Zealand Pharma AS Quarterly Data

per share eps CPI Adj_EPS
201609 -0.039 100.200 -0.048
201612 0.055 100.300 0.067
201703 -0.030 101.200 -0.036
201706 -0.111 101.200 -0.135
201709 -0.048 101.800 -0.058
201712 -0.115 101.300 -0.140
201803 -0.105 101.700 -0.127
201806 -0.113 102.300 -0.136
201809 0.937 102.400 1.125
201812 -0.130 102.100 -0.157
201903 -0.125 102.900 -0.149
201906 -0.131 102.900 -0.157
201909 -0.101 102.900 -0.121
201912 -0.161 102.900 -0.192
202003 -0.147 103.300 -0.175
202006 -0.047 103.200 -0.056
202009 -0.182 103.500 -0.216
202012 -0.317 103.400 -0.377
202103 -0.185 104.300 -0.218
202106 -0.223 105.000 -0.261
202109 -0.146 105.800 -0.170
202112 -0.197 106.600 -0.227
202203 -0.153 109.900 -0.171
202206 -0.314 113.600 -0.340
202209 -0.085 116.400 -0.090
202212 -0.192 115.900 -0.204
202303 -0.108 117.300 -0.113
202306 -0.160 116.400 -0.169
202309 0.035 117.400 0.037
202312 -0.135 116.700 -0.142
202403 -0.108 118.400 -0.112
202406 -0.135 118.500 -0.140
202409 -0.112 118.900 -0.116
202412 -0.116 118.900 -0.120
202503 -0.137 120.200 -0.140
202506 3.266 120.700 3.327
202509 -0.181 121.600 -0.183
202512 -0.166 121.200 -0.168
202603 -0.173 121.680 -0.175
202606 1.705 122.970 1.705

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $0.06 mean?
Zealand Pharma AS (ZLDPY) has a E10 of $0.06 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Zealand Pharma AS and its competitors.
Is Zealand Pharma AS's E10 too high?
Zealand Pharma AS's current E10 is $0.06. Overall, Zealand Pharma AS has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's E10 compare to VRTX and REGN?
Zealand Pharma AS's E10 of $0.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Zealand Pharma AS and its competitors. Zealand Pharma AS's current E10 is $0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPY) is currently considered Possible Value Trap. The stock's GF Value™ is $393.56, compared to a current price of $9.31 — trading 97.6% below its estimated fair value. The current E10 is $0.06. Zealand Pharma AS's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPY), the current E10 is $0.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zealand Pharma AS (ZLDPY) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of $9.31 is trading 97.6% below its estimated GF Value™ of $393.56. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for ZLDPY:

  • E10: $0.06
  • GF Value™: $393.56 vs. price of $9.31 (97.6% below fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the ZLDPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
42GF Score

Get the complete analysis for ZLDPY

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.31
Price
$393.56
GF Value